Drug intelligence / Profile preview

velmupressin

Development stage: Phase 2
Lead developer: Ferring Pharmaceuticals
Modality: Peptides, Small Molecules
Administration: Oral

Overview

Velmupressin (FE 201836) is an investigational small molecule drug developed by Ferring Pharmaceuticals for the treatment of nocturia, particularly nocturia due to nocturnal polyuria. It acts as an agonist of the vasopressin V2 receptor (AVPR2) in the kidneys, promoting water reabsorption and thereby reducing urine production at night. Velmupressin is designed to have a more predictable and rapid elimination profile compared to desmopressin, potentially lowering the risk of excessive water retention and associated side effects. The drug has completed Phase 2 clinical trials but has not been approved for any indication.

Other names: velmupressin

Targets

AVPR2 (Arginine vasopressin V2 receptor)

Beyond the preview

Go deeper on velmupressin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on velmupressin.

Explore the full profile